Feline Upper Respiratory Infections: Chlamydia felis and Bordetella bronchiseptica

Introduction

Feline upper respiratory infection (URI) is a multifactorial disease complex with viral and bacterial etiologies. Although viral agents such as feline herpesvirus-1 (FHV-1) and feline calicivirus (FCV) are the most commonly identified primary pathogens, bacterial agents including Chlamydia felis and Bordetella bronchiseptica play a significant role in both primary and secondary infections. Accurate diagnosis of these bacterial pathogens is critical for appropriate antimicrobial therapy and management of outbreaks, particularly in multi-cat environments such as shelters and breeding catteries. This article provides a detailed technical reference on C. felis and B. bronchiseptica infections in cats, focusing on pathogenesis, clinical signs, diagnostic differentiation using molecular techniques, and evidence-based treatment protocols.

Chlamydia felis

Taxonomy and Microbiology

Chlamydia felis is an obligate intracellular Gram-negative bacterium belonging to the family Chlamydiaceae. It was previously classified as Chlamydia psittaci var. felis before reclassification based on molecular analyses. The organism shares a characteristic biphasic developmental cycle with other chlamydiae, alternating between infectious elementary bodies (EBs) and metabolically active reticulate bodies (RBs). EBs are metabolically inert, environmentally stable, and responsible for host-to-host transmission. After attachment and internalization into host epithelial cells via endocytosis, EBs differentiate into RBs, which replicate within a membrane-bound inclusion vacuole. RBs then redifferentiate into EBs, which are released upon host cell lysis to infect adjacent cells or new hosts.

Pathogenesis and Host Interaction

C. felis exhibits a strict tropism for conjunctival epithelium, with secondary predilection for respiratory and reproductive tract mucosa. The primary adherence mechanism involves interaction between chlamydial outer membrane proteins and host cell glycosaminoglycan receptors. Following internalization, the bacterium evades host immune detection by inhibiting phagolysosomal fusion and modulating apoptosis pathways. The inflammatory response, driven by host cell release of cytokines including interleukin-8 and tumor necrosis factor-alpha, contributes to the characteristic neutrophilic and lymphoplasmacytic infiltrates observed in infected conjunctival tissue.

Clinical Presentation in Cats

The hallmark of C. felis infection is conjunctivitis, which may be unilateral at onset but typically becomes bilateral within days. Clinical signs include:

• Serous to mucopurulent ocular discharge
• Chemosis (conjunctival edema)
• Blepharospasm
• Hyperemia of the nictitating membrane and palpebral conjunctiva
• Follicular hyperplasia of the conjunctival lymphoid tissue

Mild upper respiratory signs, such as sneezing and serous nasal discharge, may be present but are less prominent than those observed with FHV-1 or FCV infections. Systemic signs are uncommon. In chronic or untreated cases, persistent low-grade conjunctivitis can lead to conjunctival scarring and symblepharon formation.

Epidemiology and Transmission

C. felis is shed in ocular and nasal secretions, with transmission occurring through direct contact with infected cats or fomites. The bacterium is moderately stable in the environment compared to FHV-1 but is susceptible to desiccation and common disinfectants. Carrier states are recognized, with intermittent shedding persisting for months after resolution of clinical signs. Prevalence estimates vary widely depending on population studied, with higher rates in multi-cat environments and kittens.

Bordetella bronchiseptica

Taxonomy and Microbiology

Bordetella bronchiseptica is a Gram-negative, aerobic, motile coccobacillus belonging to the family Alcaligenaceae. This bacterium is closely related to Bordetella pertussis and Bordetella parapertussis, the causative agents of whooping cough in humans, with which it shares high genomic homology. B. bronchiseptica is a respiratory pathogen of multiple mammalian species, including swine, dogs, and cats. The bacterium possesses a polysaccharide capsule and expresses a range of virulence factors, including filamentous hemagglutinin, pertactin, fimbriae, and a type III secretion system that mediates cytotoxicity toward host respiratory epithelial cells. The bacterium also produces tracheal cytotoxin, a peptidoglycan fragment that inhibits ciliary function and causes epithelial cell damage.

Pathogenesis and Host Interaction

B. bronchiseptica initially adheres to ciliated respiratory epithelium via filamentous hemagglutinin and fimbriae. The type III secretion system injects effector proteins into host cells, disrupting signaling pathways and inducing apoptosis. Tracheal cytotoxin inhibits ciliary motility and stimulates production of nitric oxide, contributing to epithelial damage and mucous hypersecretion. The bacterium can also survive within alveolar macrophages, establishing a persistent infection in some hosts. The host inflammatory response is characterized by neutrophilic infiltration, which contributes to the mucopurulent exudate observed clinically.

Clinical Presentation in Cats

The clinical presentation of B. bronchiseptica infection in cats overlaps with viral URI but has distinguishing features. Typical signs include:

• Sneezing and coughing (more prominent than with C. felis)
• Serous to mucopurulent nasal discharge
• Ocular discharge, though conjunctivitis is less severe than with C. felis
• Submandibular lymphadenopathy
• In severe cases, bronchopneumonia manifesting as fever, lethargy, inappetence, and increased respiratory effort

Kittens are most susceptible to severe disease. Coinfection with viral agents such as FHV-1 or FCV, or with feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV), can exacerbate clinical severity.

Epidemiology and Transmission

Transmission occurs via direct contact with respiratory secretions, aerosolization from coughing and sneezing, and contaminated fomites. B. bronchiseptica can survive for weeks in moist environments, facilitating indirect transmission. Latent or asymptomatic carrier animals are important reservoirs in shelter and cattery settings. Zoonotic transmission of B. bronchiseptica from cats to immunocompromised humans has been reported but is considered rare.

Diagnostic Differentiation

Clinical Differentiation

Clinical signs alone are insufficient to differentiate bacterial from viral URI etiologies. However, certain patterns may increase suspicion for specific agents. Predominantly ocular signs with marked conjunctivitis and minimal respiratory signs strongly suggest C. felis infection. Productive coughing, particularly in young kittens, raises suspicion for B. bronchiseptica. Concurrent oral ulceration is highly suggestive of FCV. Dendritic corneal ulcers, characteristic of FHV-1, may be detected using fluorescein staining.

Acute Phase Protein Assessment

Serum acute phase protein concentrations show potential as adjunctive diagnostic tools. Gareis and Schulz [1] evaluated serum amyloid A and haptoglobin in cats with respiratory disease. While not specific for bacterial versus viral etiology, elevated acute phase proteins may help identify cats with more severe systemic inflammation requiring intensive intervention.

Molecular Detection

Nucleic acid amplification testing (NAAT), particularly polymerase chain reaction (PCR), is the diagnostic method of choice for identifying C. felis and B. bronchiseptica in feline respiratory specimens. Multiplex PCR panels allowing simultaneous detection of multiple respiratory pathogens are widely available. This topic is covered in detail in the article Feline Upper Respiratory Tract Infection Complex: Multiplex PCR Panel Interpretation and Treatment Algorithms.

Specimen Collection

For C. felis detection, conjunctival swabs are the specimen of choice. The swab should be rolled gently across the lower conjunctival fornix to collect epithelial cells, as the organism is intracellular. For B. bronchiseptica, deep nasopharyngeal or oropharyngeal swabs are preferred. Cotton-tipped or Dacron swabs with plastic shafts are recommended; calcium alginate swabs inhibit PCR. Swabs should be placed into sterile transport medium and refrigerated if processing is delayed.

PCR Assay Principles

Real-time PCR assays typically target the ompA gene (encoding the major outer membrane protein) for C. felis and the flaA gene (encoding flagellin) for B. bronchiseptica. These targets provide high sensitivity and specificity. Probes labeled with fluorophores enable real-time detection and quantification. Assay sensitivity approaches 100% for clinical specimens from actively infected cats. False negatives can occur with inadequate cellular sampling or sample degradation. False positives due to contamination are rare with rigorous laboratory protocols.

Diagnostic Algorithm

A structured diagnostic algorithm facilitates efficient differentiation of feline URI pathogens.

flowchart TD
    A[Cat presenting with URI signs], > B{Perform physical exam and ocular exam}
    B, > C[Collect conjunctival swab and deep nasopharyngeal swab]
    C, > D[Submit for multiplex PCR panel]
    D, > E{PCR results}
    E, > F[C. felis positive]
    E, > G[B. bronchiseptica positive]
    E, > H[FHV-1 or FCV positive]
    E, > I[All pathogens negative]
    F, > J[Initiate doxycycline therapy]
    G, > J
    H, > K[Supportive care, consider antivirals]
    I, > L[Repeat testing, consider culture or paired serology]
    J, > M[Re-evaluate at 2 weeks; repeat PCR if no improvement]
    M, > N{Improved?}
    N, > O[Complete 4-week course]
    N, > P[Consider alternative diagnosis or resistance testing]

Treatment

Antibiotic Therapy for Chlamydia felis

Doxycycline is the first-line antimicrobial for C. felis infection. Doxycycline achieves high intracellular concentrations and effectively targets the metabolically active RB stage. The recommended dosage is 10 mg/kg orally every 12 hours or 5 mg/kg orally every 12 hours for 28 days. Treatment should be continued for at least 2 weeks beyond resolution of clinical signs to eliminate the carrier state. Doxycycline hyclate or monohydrate may be used. Tablets are preferable to suspensions due to palatability issues. Esophageal stricture is a potential adverse event with doxycycline administration in cats; the tablet should be followed with a water bolus or a small amount of food. Commercial doxycycline formulations specifically designed for cats reduce this risk. The article Point-of-Care Lactate and Blood Gas Analyzers in Canine Emergency Triage: Prognostic Accuracy and Clinical Protocols discusses critical care monitoring protocols that may be relevant in severe cases with systemic involvement.

Alternative antibiotics include tetracycline ophthalmic ointments for topical treatment of conjunctivitis. However, topical therapy alone is rarely sufficient to eradicate infection due to systemic dissemination. Azithromycin at 10 mg/kg orally every 24 hours for 7 days, then every 48 hours for 14 days, has been used but is considered second-line.

Antibiotic Therapy for Bordetella bronchiseptica

Doxycycline is also the first-line antibiotic for B. bronchiseptica infection. The dosage regimen and duration are identical to that used for C. felis. Tetracyclines exhibit good in vitro activity against this organism and achieve adequate respiratory tissue concentrations. Alternatives based on susceptibility testing include fluoroquinolones (e.g., enrofloxacin, marbofloxacin) and potentiated sulfonamides. Penicillins and cephalosporins are often ineffective due to beta-lactamase production.

Duration of Therapy and Monitoring

A minimum 14-day treatment course is recommended for B. bronchiseptica. Clinical improvement is typically observed within 48 to 72 hours. Persistent or recurrent signs after treatment should prompt repeat PCR testing to confirm clearance and to rule out coinfection, antimicrobial resistance, or poor owner compliance. Susceptibility testing should be considered for recurrent cases.

Supportive Care

Supportive care is critical in managing feline URI regardless of etiology. This includes:

• Ocular lubrication with artificial tears or ophthalmic ointments
• Gentle cleaning of ocular and nasal discharge
• Humidification therapy to reduce nasal congestion
• Nutritional support for anosmic cats, including warmed and strongly aromatic foods
• In severe cases with bronchopneumonia, oxygen supplementation and fluid therapy

Cats with concurrent immunosuppressive conditions such as FeLV or FIV infection may require extended therapy. Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV): Point-of-Care Testing and Clinical Management offers further detail on managing these comorbidities.

Environmental Management and Biosecurity

Control of bacterial URIs in multi-cat environments requires strict biosecurity. Infected cats should be isolated from susceptible animals. Cages, bowls, and litter boxes should be cleaned with disinfectants effective against both organisms. Chlorine dioxide, accelerated hydrogen peroxide, and quaternary ammonium compounds are effective against C. felis and B. bronchiseptica. Hand hygiene between handling cats is essential. Vaccination against C. felis and B. bronchiseptica is available in some regions as part of combination feline URI vaccines; these vaccines do not prevent infection but reduce clinical severity and shedding.

Comparative Host Range and Zoonotic Considerations

B. bronchiseptica is a well recognized pathogen of dogs, swine, and rabbits. Transmission of B. bronchiseptica from cats to immunocompromised humans is possible but uncommon. C. felis is predominantly a feline pathogen; while it is genetically closely related to C. psittaci, zoonotic transmission from cats to humans has been reported in rare instances and typically results in mild conjunctivitis. The article Psittacosis in Birds and Humans: Chlamydia psittaci Diagnostics and One Health Transmission provides relevant background on chlamydial diagnostics and transmission.

Avian influenza A(H5N1) has been identified in domestic cats [2, 3], highlighting the need for differential diagnosis of respiratory signs in cats with potential exposure to infected poultry or wild birds. Although influenza viruses are not the focus of this article, the possibility of emerging viral etiologies should not be overlooked. Doğan et al. [4] investigated gammaherpesvirus in cats with and without upper respiratory disease, further illustrating the breadth of potential infectious causes.

Conclusion

C. felis and B. bronchiseptica are important bacterial causes of feline URI, each with distinct clinical presentations, diagnostic approaches, and treatment protocols. PCR-based multiplex panels are the gold standard for etiological differentiation. Doxycycline remains the cornerstone of antimicrobial therapy for both pathogens. Accurate diagnosis is essential for appropriate case management and infection control in multi-cat environments. The ongoing emergence of novel respiratory pathogens and the potential for cross-species transmission underscore the need for continued surveillance and diagnostic vigilance.

References

[1] Gareis H, Schulz B. Evaluation of amyloid A and haptoglobin in the serum of cats with respiratory diseases. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42109870/.

[2] Dressler A, Wagner-Wiening C, Tegtmeyer B, et al. Highly pathogenic avian influenza A(H5N1) in poultry and domestic cats and occupational exposure among veterinary and other first responders, Germany, February 2026. Euro Surveill. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42141860/.

[3] Vaughan A, Joyce A, Traub E, et al. Serologic Evidence of Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Veterinary Professional Exposed to an Infected Domestic Cat - Los Angeles County, California, December 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42096344/.

[4] Doğan F, Acar G, Fedai T, et al. Investigation of the presence of gammaherpesvirus infections in cats with and without upper respiratory tract disease. Comp Immunol Microbiol Infect Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42035571/.

[5] Sasvari H, Sherry L, Logan N, et al. Serological response to feline coronavirus in the UK domestic cat population. J Gen Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42138717/.

[6] Du YT, Hu X, Zhu ZG, et al. The impact of nonpharmaceutical interventions (NPIs) on rabies post-exposure prophylaxis: A comparative study in Wuhan, 2022 vs. 2023. Hum Vaccin Immunother. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42116803/.

[7] Bai Y, Zhao J, Wang Z, et al. A case of Rickettsia felis caused pneumonia and diagnosed by clinical analysis and Targeted Next-Generation Sequencing (tNGS) using Bronchoalveolar Lavage Fluid (BALF): A case report and literature review. J Infect Public Health. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41935438/.

[8] Foster A, Kerr M, Gu J. Sinonasal Nocardia farcinica in a cat with comorbidities. Can Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41929723/.

[9] Dzimira S. Feline Cryptococcosis: Two Case Reports and a Literature Review. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41901732/.

[10] Foksiński P, Kaczorek-Łukowska E, Szyryńska N, et al. Preliminary study on the effects of sub-MIC concentrations of octenidine and polyhexanidine on biofilms produced by animal isolates of Pseudomonas aeruginosa. BMC Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41888683/.

[11] Kaur J, Giannino D, Taylor R, et al. Nodular pyogranulomatous pneumonia associated with Besnoitia darlingi infection in a cat. J Vet Diagn Invest. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41782300/.

[12] Shao P, Lian Y, Liu X, et al. Rapid and sensitive detection of feline herpesvirus-1 using fluorescent microspheres as labels for immunochromatographic test strips. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41779066/.

[13] Nooruzzaman M, Butt SL, Rani R, et al. The ORF6 accessory protein contributes to SARS-CoV-2 virulence and pathogenicity in the naturally susceptible feline model of infection. J Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41757964/.

[14] Mitra N, Jadhao A, Dhende AV, et al. First report of fatal feline pulmonary tuberculosis caused by the emerging zoonotic pathogen Mycobacterium orygis in a cat from India. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41712109/.

[15] Yuan Y, Geng Y, Zhu Q, et al. Comparable immune escape capacity for NB.1 with that of JN.1 variant and survey of infection with severe acute respiratory syndrome coronavirus 2 variants among Chinese Felis silvestris catus. Front Immunol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41676134/.